{
    "nct_id": "NCT05948826",
    "official_title": "A Phase 1, First in Human, Dose-Escalation Study of TORL-3-600 in Participants With Advanced Cancer",
    "inclusion_criteria": "* Advanced solid tumor\n* Measurable disease, per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade â‰¤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements\n* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-3-600\n* Progressive or symptomatic brain metastases\n* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection\n* History of significant cardiac disease\n* History of myelodysplastic syndrome (MDS) or AML\n* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded\n* If female, is pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}